These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

855 related items for PubMed ID: 28302310

  • 1. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Patel BD, Bhadada SV, Ghate MD.
    Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
    Li N, Wang LJ, Jiang B, Guo SJ, Li XQ, Chen XC, Luo J, Li C, Wang Y, Shi DY.
    Bioorg Med Chem Lett; 2018 Jul 01; 28(12):2131-2135. PubMed ID: 29773502
    [Abstract] [Full Text] [Related]

  • 3. Design and Discovery of Novel 1,3,5-Triazines as Dipeptidyl Peptidase-4 Inhibitor against Diabetes.
    Wang Y, Tang X, Yi L.
    Pharmacology; 2019 Jul 01; 103(5-6):273-281. PubMed ID: 30799431
    [Abstract] [Full Text] [Related]

  • 4. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
    Deng X, Han L, Zhou J, Zhang H, Li Q.
    Bioorg Chem; 2017 Dec 01; 75():357-367. PubMed ID: 29096096
    [Abstract] [Full Text] [Related]

  • 5. Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.
    Li Q, Meng L, Zhou S, Deng X, Wang N, Ji Y, Peng Y, Xing J, Yao G.
    Eur J Med Chem; 2019 Oct 15; 180():509-523. PubMed ID: 31336309
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Diabetes mellitus Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and de novo Evolution.
    Musoev A, Numonov S, You Z, Gao H.
    Molecules; 2019 Aug 07; 24(16):. PubMed ID: 31394858
    [Abstract] [Full Text] [Related]

  • 8. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA.
    Eur J Pharmacol; 2011 Feb 10; 652(1-3):157-63. PubMed ID: 20540938
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors.
    Deng X, Shen J, Zhu H, Xiao J, Sun R, Xie F, Lam C, Wang J, Qiao Y, Tavallaie MS, Hu Y, Du Y, Li J, Fu L, Jiang F.
    Bioorg Med Chem; 2018 Feb 15; 26(4):903-912. PubMed ID: 29373269
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1-c][1,2,4]-triazines and Pyrazolo[5,1-c][1,2,4]triazines as Potential Antidiabetic Agents.
    Rusinov VL, Sapozhnikova IM, Bliznik AM, Chupakhin ON, Charushin VN, Spasov AA, Vassiliev PM, Kuznetsova VA, Rashchenko AI, Babkov DA.
    Arch Pharm (Weinheim); 2017 May 15; 350(5):. PubMed ID: 28393419
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.